Results 91 to 100 of about 63,889 (276)
Measuring infliximab and adalimumab drug and antibodies in Crohn's disease and ulcerative colitis
, 2020 The anti-TNF therapies infliximab and adalimumab have revolutionized the treatment of inflammatory bowel disease, being very effective in many patients.
core
Food Safety and Health, EarlyView.In this review, we critically summarized the application of natural polysaccharides (NPs) for the treatment of IBD. This approach combines, in a unique way (right), the basic structure–activity relationships of NPs from different origins (left) with their multipronged mode of action, which involves modulation of the gut microbiota and other ...
Felix Danso +3 more
wiley +1 more source
Food Safety and Health, EarlyView.Biosensors enable rapid, sensitive, and portable detection of pathogens, contaminants, allergens, and food adulteration. Integration with smart packaging, smartphones, IoT, and machine learning supports real‐time monitoring and intelligent decision‐making, whereas microfluidics, biodegradable materials, explainable AI, and blockchain offer pathways ...
Mohima Akther Any +7 more
wiley +1 more source
Serum infliximab concentrations in psoriatic patients treated with infliximab: a systematic review
, 2015 The efficacy of infliximab is influenced by individual variability in its pharmacokinetics and pharmacodynamics. Serum infliximab concentrations could therefore be related to the efficacy and tolerance of infliximab, and assist adjustment of treatment ...
Machet, Laurent +5 more
core +1 more source
iMetaMed, EarlyView.Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the intestine associated with an imbalance in intestinal homeostasis. m6A‐modifying enzymes, consisting of m6A writers, erasers and readers, plays a pivotal role in the pathogenesis and progression of IBD by affecting four intestinal barriers, including the intestinal mechanical ...
Jiaxian Guo +4 more
wiley +1 more source
Infliximab dependency in children with Crohn's disease
, 2009 Udgivelsesdato: 2009-AprBACKGROUND: Recently, infliximab dependency has been described. AIM: To assess frequency of ID in 82 consecutive Crohn's disease children treated with infliximab 2000-2006 and to describe clinical and genetic predictors of long ...
Nevoral, J +13 more
core +1 more source
Journal of Pediatric Gastroenterology and Nutrition, EarlyView.Abstract Objectives Despite advances in pediatric inflammatory bowel disease (PIBD) with biologics, remission rates remain at 47%–60% with loss‐of‐response rates at 60%–68%. Evidence for efficacy of dual biologic therapy (DBT) with anti‐tumor necrosis factor alpha therapy (anti‐TNF‐α)‐ vedolizumab (VDZ) for children refractory to anti‐TNF‐α therapy is ...
Jonathan E. M. O'Donnell +6 more
wiley +1 more source
Infliximab therapy in pediatric Crohn’s disease: a review
, 2010 Kalyan Ray Parashette1, Raghavendra Charan Makam2, Carmen Cuffari31Department of Pediatrics, University of Illinois at Chicago, Chicago, IL, USA; 2Department of Internal Medicine, Berkshire Medical Center, Pittsfield, MA, USA; 3Division of Pediatric ...
Carmen Cuffari +2 more
core
JPGN Reports, EarlyView.Abstract Infantile‐onset inflammatory bowel disease (IOIBD) is a rare and severe subset of very‐early‐onset IBD, often associated with immune dysregulation and poor response to conventional therapies. Data regarding the use of Janus kinase inhibitors (JAKI) in this population is limited.
Smridhi Mahajan +2 more
wiley +1 more source
Long-term safety and efficacy of infliximab for the treatment of ankylosing spondylitis
, 2015 Ofir Elalouf, Ori Elkayam Department of Rheumatology, Sackler Faculty of Medicine, Tel Aviv Medical Center, Tel Aviv, Israel Abstract: The introduction of TNFα blockers has revolutionized the treatment of ankylosing spondylitis (AS).
Elalouf O, Elkayam O
core